Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


With claimed designated perfecting feature in contents (e.g., excipient, lubricant, etc.)

Subclass of:

424 - Drug, bio-affecting and body treating compositions

424400000 - PREPARATIONS CHARACTERIZED BY SPECIAL PHYSICAL FORM

424451000 - Capsules (e.g., of gelatin, of chocolate, etc.)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20090196919OXCARBAZEPINE DOSAGE FORMS - The present invention relates to dosage forms of oxcarbazepine for oral administration that contain oxcarbazepine having a median particle size of from about 14 μm to about 30 μm and to processes for the preparation of such dosage forms. The dosage form may be a solid or a liquid dosage form. The solid dosage form may be in the form of a tablet, a capsule, or a granulate. The liquid dosage form may be in the form of a solution or a suspension.08-06-2009
20120171284CELECOXIB COMPOSITIONS - Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.07-05-2012
20080260814INJECTION MOULDING PROCESS FOR NEUTRAL AND ACID-GROUP-CONTAINING (METH)ACRYLATE COPOLYMERS - Processes for producing moldings by injection moulding, include melting a mixture made from a (meth)acrylate copolymer and a release agent, devolatilizing the mixture, injecting the molten and devolatilized mixture into a mold cavity of an injection mold, cooling the molten mixture, and removing the resultant molding from the mold.10-23-2008
20110195117CONTROLLED RELEASE COMPOSITIONS OF ROPINIROLE - A novel oral controlled release pharmaceutical composition comprising a therapeutically effective amount of active substance, ropinirole or a pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) or hydrate(s) thereof, one or more controlled release agent(s), optionally one or more pharmaceutically acceptable excipient(s) and an extended release coating, wherein the said composition provides controlled release of the active agent with reduced initial burst release.08-11-2011
20100074947Pharmaceutical Formulations - The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.03-25-2010
201202442174-METHYLPYRAZOLE FORMULATIONS - Provided herein are 4-methylpyrazole (4-MP) formulations, stable under storage conditions of up to about 55° C.09-27-2012
20120183607STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS - The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.07-19-2012
20090155354DISPENSING ENCAPSULATED LIQUIDS INTO BODY CAVITIES - Body tissue or cavities are treated by inserting a membrane module containing a substance for treating a condition of the cavity or tissue. The substance is enclosed in a membrane that melts, dissolves, or dissipates in the environment of the cavity such as a vagina to release the substance into the cavity.06-18-2009
20100104634PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE - The invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.04-29-2010
20130089604Solid Oral Dosage Form Containing An Enhancer - The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.04-11-2013
20090304787DRUG DELIVERY COMPOSITION - A drug delivery composition that comprises extruded spheroids. The spheroids comprise at least one active pharmaceutical ingredient; at least one extrusion-spheronization aid; at least one superdisintegrant; and at least one glidant, at least one lubricant, and/or at least one oil. The spheroids may also be coated. In a further aspect, a drug delivery composition that comprises coated spheroids that have inert spheroids and at least one coating for the spheroids. The coating comprises at least one active pharmaceutical ingredient and at least one superdisintegrant.12-10-2009
20090304786Stable Dosage Forms of an Antidepressant - The present invention relates to stable solid dosage forms of an antidepressant. More particularly, the present invention relates to stable solid dosage forms of bupropion hydrochloride. The present invention also relates to a process for the preparation of stable solid dosage forms of bupropion hydrochloride.12-10-2009
20090110722Composition - A pharmaceutical composition comprising licarbazepine acetate, especially eslicarbazepine acetate, in combination with suitable excipients, in particular a binder, and a disintegrant. Also disclosed is a granulation process, especially a wet granulation process, for making the pharmaceutical composition.04-30-2009
20090041839PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN - The present invention provides pharmaceutical compositions comprising an allosteric adenosine A02-12-2009
20090041838Anti-Misuse Microparticulate Oral Drug Form - The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. Another aim of the invention is to provide novel analgesic drugs which can be used to: prevent the misuse of, and addiction to certain analgesics and/or to control plasma concentration variability and/or to facilitate oral; administration; and/or to combine analgesics with one another and/or with one or more active ingredients in the same oral form. More specifically, the invention relates to a solid oral drug form comprising anti-misuse means and at least one active ingredient, which is characterized in that: at least part of the active ingredient is contained in microparticles; and the anti-misuse means comprise anti-crushing means (a) which enable the microparticles of the active ingredient to resist crushing, such as to prevent the misuse thereof. According to the invention, the drug form can also comprise means (b) for preventing the misuse of the active ingredient following a possible liquid extraction process.02-12-2009
20110014281DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF POORLY WATER SOLUBLE PHARMACEUTICALLY ACTIVE SUBSTANCES - This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.01-20-2011
20110014280SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METHODS - A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.01-20-2011
20090269399PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.10-29-2009
20090269398Compositions for the encapsulation of natural product extracts in oil medium in hard gelatin capsules and a method of encapsulation - The present invention relates to compositions of natural extracts in oil medium, prepared in non-free-flowing formulations, and encapsuled in hard gelatin capsules, without post-fill sealing. These compositions comprise a therapeutically effective amount of at least one natural extract in oil medium, the composition suitable for treating a medical condition, and at least one oil-absorbent ingredient in powder form. More specifically, the natural extract in the composition can be an extract of 10-29-2009
20120225118COMPOSITIONS FOR DELIVERY OF INSOLUBLE AGENTS - Compositions and methods of making the same for improving the bioavailability of a substantially water-insoluble pharmacologically active agent are described. The composition includes a substantially water-insoluble pharmacologically active agent, and a substantially water-insoluble matrix forming material comprising enzyme digestible or bile soluble nutrients, wherein the substantially water-insoluble pharmacologically active agent is dispersed in a solid matrix and wherein said pharmacologically active agent in said matrix is substantially free of the original crystalline form.09-06-2012
20120114750PHARMACEUTICAL COMPOSITION 271 - The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.05-10-2012
20120269890PROCESS FOR OBTAINING A ROSUVASTATIN CALCIUM COMPOSITION AND OBTAINED PRODUCT - The present invention describes a rosuvastatin calcium composition that does not require tribasic phosphate salts to be stable and that also has suitable bioavailability, and is helpful in reducing lipid and/or cholesterol levels in the body, as well as the manufacturing method of this composition.10-25-2012
20100080846DIPYRIDAMOLE AND ACETYLSALICYLIC ACID FORMULATIONS AND PROCESS FOR PREPARING SAME - The present invention provides pharmaceutical formulations of dipyridamole and acetylsalicylic acid, methods of making thereof, and methods of using thereof.04-01-2010
20090011009Microspheres comprising nanocapsules containing a lipophilic drug - The present invention provides microspheres comprising a plurality of nanocapsules accommodated in a gel forming polymer, the plurality of nanocapsules comprising an oil core carrying a non hydrophilic active agent and a shell of polymeric coating. The invention also provides a method for preparing the microspheres of the invention, pharmaceutical compositions comprising the same as well as methods of use of the microspheres, specifically, in therapeutic, cosmetic and diagnostic applications.01-08-2009
20110280936Self Breaking Tablets - Self-breaking tablet and capsule formulations with a similar in vitro drug release profile for whole tablet and when broken and/or a bioequivalent drug release profile when taken whole or when broken are provided. Methods for production of these formulations and tablets and their administration are also provided.11-17-2011
20110142926Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.06-16-2011
20110280937HARD CAPSULE - The object of the invention is to provide a hard capsule that is excellent in stability even when filled with a solvent for dissolving a poorly soluble pharmaceutical active ingredient, and that has excellent mechanical strength in a low-humidity environment. The invention provides a hard capsule having a film containing (A) a polymer or copolymer obtained by polymerizing or copolymerizing at least one polymerizable vinyl monomer represented by Formula (1): H11-17-2011
20110280938SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION OF QUETIAPINE AND PROCESS FOR PREPARATION THEREOF - The present invention relates to sustained release pharmaceutical composition of quetiapine, and process for preparing such composition. More particularly, it relates to sustained release pharmaceutical composition of quetiapine comprising a non gelling agents such as carrageenan and pharmaceutically acceptable excipients.11-17-2011
20110300209MODIFIED RELEASE SOLID PHARMACEUTICAL COMPOSITIONS OF TRIMETAZIDINE AND PROCESS THEREOF - There is provided a modified release solid pharmaceutical composition comprising Trimetazidine and polyethylene oxide, wherein the composition does not include any lubricant.12-08-2011
20100297220Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders - Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at lest one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid.11-25-2010
20100143461PALONOSETRON FORMULATION - The present invention provides solid oral formulations of palonosetron or salts thereof.06-10-2010
20110117190Pharmaceutical Formulations - The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection moulding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.05-19-2011
20100143459PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR - A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.06-10-2010
20110217369FENOFIBRATE COMPOSITIONS - The present invention relates to a fenofibrate composition comprising: fenofibrate, a surfactant, a hydrophilic polymer and one or more anti-foaming agents. The invention also relates to a novel process for preparing said composition that has enhanced dissolution and absorption characteristics.09-08-2011
20110268792SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS - The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.11-03-2011
20110262533PHARMACEUTICAL FORMULATION FOR USE IN HIV THERAPY - The invention discloses a formulation prepared by granulating at least one anti-retro viral drug and at least one pharmaceutically acceptable additive, using an organic solvent; milling the product; finally processing the milled product to form tablets or capsules.10-27-2011
20100112045SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof.05-06-2010
20110104267Pharmaceutical compositions of antiretrovirals - The present invention relates to the stable pharmaceutical dosage forms of combination of antiretroviral agents. More particularly, the present invention relates to stable pharmaceutical dosage forms of Lamivudine, Zidovudine and Nevirapine, prepared by granulation technology.05-05-2011
20120107395Probiotic Soft Gel Compositions - Soft gel capsules are formed from an outer gelatin-containing shell and a filling. The filling includes a probiotic and a dessicant.05-03-2012
20090263476Composition of Rapid Disintegrating Direct Compression Buccal Tablet - A composition of a rapidly disintegrating buccal dosage form containing a drug, at least one non-effervescent base such as an alkali metal or alkaline earth metal oxide or hydroxide, and a disintegrant. The base regulates the pH gradient to deliver the drug to the buccal, sublingual or oral mucosal membranes at a desired rate of absorption. The composition is micronized for uniform distribution, and the drug is converted from ionized form to unionized form, without the use of an effervescent agent.10-22-2009
20110171295IMMEDIATE RELEASE COMPOSITIONS OF ACID LABILE DRUGS - The present invention provides a method of creating a macro environment in the stomach for immediate release of acid labile compounds stable at alkaline or near alkaline pH comprising the step of administering a composition comprising acid labile compound stable at alkaline or near alkaline pH together with a water soluble buffer, a water insoluble buffer, a disintegrant and pharmaceutically acceptable excipients. The present invention also provides a pharmaceutical composition of a multi component system in which one component essentially contains an acid labile drug and the other component comprises a fast releasing buffer composition along with pharmaceutically acceptable excipients for oral administration and ingestion by a subject, and process for preparing the same.07-14-2011
20110171297SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE - The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. (2). Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. (3). Exhibits linearity between the strength dosage form and the (total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. (4). Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: (1). A functional core comprising the active ingredient, especially the water-soluble drug Venlafaxine HCl and appropriate excipients. (2). A functional coating layer or film that reduces the initial surface of the core that is available for the release of the water-soluble drug Venlafaxine HCl phenomenon.07-14-2011
20110171296METHOD AND PREPARATION FOR BINDING ACETALDEHYDE IN SALIVA, THE STOMACH AND THE LARGE INTESTINE - The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds.07-14-2011
20080311188SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A SIP RECEPTOR AGONIST AND A SUGAR ALCOHOL - A solid pharmaceutical composition suitable for oral administration, comprising: 12-18-2008
20100129442Oral Multi-Functional Pharmaceutical Capsule Preparations Of Proton Pump Inhibitors - An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate. In another embodiment, the oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a population of a pharmaceutical active; a population of a basic substance; a population of enteric coated pharmaceutical active; and a population of enteric coated basic substance. The composition can provide multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma.05-27-2010
20120294936REDUCED MASS METFORMIN FORMULATIONS - The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules.11-22-2012
20120294937NEW PHARMACEUTICAL DOSAGE FORM FOR THE TREATMENT OF GASTRIC ACID-RELATED DISORDERS - According to the invention there is provided a capsule for peroral administration to the gastrointestinal tract containing (a) a pharmacologically effective amount of a PPI or a pharmaceutically acceptable salt thereof and an enteric substance positioned to protect the PPI or salt thereof from the acidic environment of the stomach, and (b) a plurality of granules comprising a pharmacologically effective amount of a micronised H2RA or a pharmaceutically acceptable salt thereof, a disintegrant and a filler The capsules of the invention are particularly useful in the treatment of gastric acid secretion-related disorders, such as gastro-esophageal reflux disease.11-22-2012
20110206762ORAL PHARMACEUTICAL FORMULATION OF PELUBIPROFEN WITH IMPROVED DISSOLUTION RATE AND STABILITY - Disclosed is an oral pharmaceutical formulation of pelubiprofen which is improved in dissolution rate and stability. As a result of an improvement in the dissolution rate of pelubiprofen, the oral pharmaceutical formulation can show high bioavailability and thus exert pharmacological effects thereof rapidly. It also can be stored with high stability as a result of the minimal generation of related compounds.08-25-2011
20090035368EMBEDDED MICELLAR NANOPARTICLES - The present invention relates to a thermostable solid composition containing nanosized micelles, the micelles containing a poorly soluble chemical substance, such as a biologically active substance, dissolved in an auxiliary material, and the micelles being embedded in a water soluble carrier. The invention further relates to a process for preparing a thermostable solid composition and to a process for preparing pharmaceutical dosage forms comprising the same.02-05-2009
20120294938PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED ACTIVE INGREDIENT RELEASE IN THE SMALL INTESTINE AND METHOD FOR ITS PRODUCTION - Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described.11-22-2012
20080274174STABLE PANCREATIC ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.11-06-2008
20100136104NUTRITIONAL SUPPLEMENT FOR USE UNDER PHYSIOLOGICALLY STRESSFUL CONDITIONS - In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 300 mg of vitamin C; about 1200 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folate; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 300 mcg of biotin; about 50 mg of calcium; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 25 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 2 mg of lutein; about 500 mcg of lycopene; about 5 mg of pepper extract; and at least one or more excipients.06-03-2010
20100143460SOLID DOSAGE FORMS COMPRISING ALISKIREN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to a pharmaceutical formulation comprising aliskiren or a pharmaceutically acceptable salt thereof as the active ingredient, wherein the pharmaceutical formulation is present in a solid dosage form suitable for oral administration based on a granulate obtained by a hot-melt and solvent-free granulation process, and to a process for manufacturing a pharmaceutical formulation.06-10-2010
20120141580CAPSULE FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or lanthanum hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The capsules of the present invention dissolve at a similar rate before and after storage. The oral pharmaceutical capsules of the present invention can be administered to treat a patient at risk for or suffering from hyperphosphatemia, at risk for or suffering from chronic kidney disease (CKD), at risk for or suffering from soft tissue calcification associated with CKD, or at risk for or suffering from secondary hyperparathyroidism.06-07-2012
20090162429Slow-Release Composition, Method for the Preparation Thereof, and Use Thereof - The pharmaceutical or nutraceutical composition with sustained release of an active ingredient according to the present invention comprises at least one coated granule; the coated granule being composed of a particle that comprises said active ingredient and is coated with at least two coatings that comprise a combination of excipients. The present invention relates also to a process for the preparation of the composition.06-25-2009
20110206761STABLE DOSAGE FORMS OF ANTIHYPERTENSIVE AGENTS - The technical field of the present invention relates to stable solid dosage form comprising combination of antihypertensive agents. More particularly, the present invention relates to stable solid dosage form comprising combination of angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB).08-25-2011
20090035367CONTROLLED DEGRADATION OF EXPANDABLE POLYMERS IN GASTRIC VOLUME REDUCTION TREATMENT - Orally administrable polymer-carrying units for expanding in a stomach of a mammal to fill a space in the stomach, the polymer-carrying units including: a carrier; a plurality of polymer molecules expandable in aqueous solutions, releasably coupled to the carrier; and means for selectively decoupling the polymer molecules from the carrier so that the polymer molecules and carrier are released in the stomach, are provided.02-05-2009
20100151012STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PREGABALINE - Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline.06-17-2010
20130216617PHARMACEUTICAL COMPOSITIONS OF (R)-LANSOPRAZOLE - The present invention relates to stable pharmaceutical compositions of (R)-lansoprazole or pharmaceutically acceptable salts thereof and process of preparing the same. The invention particularly provides pharmaceutical compositions of optically active (R)-isomer of lansoprazole with at least two functional coating layers.08-22-2013
20090208568Gellan Seamless Breakable Capsule and Process for Manufacturing Thereof - The invention relates to a process for manufacturing a seamless breakable capsule, comprising—co-extruding an external and hydrophilic liquid phase, and an internal and lipophilic liquid phase, in order to form a capsule constituted of a core comprising the internal and lipophilic phase, and a shell comprising the external and hydrophilic phase,—immersing into an aqueous solution containing a curing agent, wherein the external liquid phase includes a gelling agent comprising gellan gum alone or in combination with another gelling agent, a filler, and a divalent metal sequestering agent, and to breakable capsules comprising a core and a shell, wherein the shell includes a gelling agent comprising gellan gum alone or in combination with another gelling agent, a filler, and a divalent metal sequestering agent.08-20-2009
20110223244ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.09-15-2011
20090087484Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules - A formulation and dosage form for enhancing the bioavailability of orally administered hydrophilic macromolecules includes a permeation enhancer, a hydrophilic macromolecule, and a carrier such as a nonionic surfactant that exhibits in-situ gelling properties. The formulation is delivered within the GI tract as a liquid having at least some affinity for the surface of the GI mucosal membrane. Once released, it is believed that the liquid formulation spreads across one or more areas of the surface of the GI mucosal membrane, where the carrier of the formulation then transitions into a bioadhesive gel in-situ. As a bioadhesive gel, the formulation presents the hydrophilic macromolecule and the permeation enhancer at the surface of the GI mucosal membrane at concentrations sufficient to increase absorption of the hydrophilic macromolecule through the GI mucosal membrane over a period of time. A dosage form incorporates the formulation and may be designed to provide the controlled release of the formulation within the GI tract over a desired period of time.04-02-2009
20110229561 Extended Release Pharmaceutical Composition Of Entacapone Or Salts Thereof - There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.09-22-2011
20090081286Extended release venlafaxine formulation - A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.03-26-2009
20090220590Triple drug combinations for psychiatric patients - The mega capsule can be prescribed by any physician, and in particular those professionals in the psychiatric field. The mega capsule will be a form of medication designed for a specific patient in mind. The capsule will help the patients understand their medications better and make it easier for them to take. The patient may only have to take the mega capsule once or twice a day and by doing that, the patient will feel more in control of their prescriptions. By inventing the mega capsule, we may lower the cost significantly for the patients. Altogether, it will make life easier for the patients and the physicians.09-03-2009
20090258065Dermatological compositions comprising avermectin nanocapsules - Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.10-15-2009
20100151011SOLID ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORMS WITH RAPID ACTIVE PRINCIPLE RELEASE - The present invention relates to solid pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide in amorphous form and/or thermodynamically metastable crystal modification and have rapid release of active ingredient, and to process for the production thereof, the use thereof as medicament, the use thereof for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and to the use thereof for producing a medicament for the prophylaxis, secondary prophylaxis and/or treatment of disorders.06-17-2010
20100015220NIACIN AND NSAID COMBINATION THERAPY - Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing comprising an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing comprising niacin, aspirin and a lipid-lowering drug other than niacin.01-21-2010
20100151013Gastric acid secretion inhibiting composition - An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.06-17-2010
20100151010MEDICAMENT IN A MULTILAYER FORM - The invention relates to a medicament in a multilayer form, containing a) a core with a pharmaceutical agent, b) an inner coating, 50 to 95 percent by weight of which arc composed of a (co)polymer comprising 95 to 100 percent by weight of radically polymerized vinylic monomers with neutral side groups and 0 to 5 percent by weight of monomers with anionic side groups, c) an outer coaling made of a copolymer comprising 75 to 95 percent by weight of radically polymerized C06-17-2010
20100178336STABILIZED AMORPHOUS FORMS OF IMATINIB MESYLATE - The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N--[4-methyl-3-( 4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.07-15-2010
20100189780Novel Powderous Medicaments Comprising Tiotropium and Salmeterol and Lactose as Carrier - The invention relates to stable preparations in powder form for inhalation comprising a tiotropium salt and salmeterol xinafoate, process for the production thereof, and the use thereof for manufacturing a medicament for the treatment of respiratory disorders, especially for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.07-29-2010
20100178333SUSTAINED RELEASE DOSAGE FORM OF PHENOTHIAZINE DERIVATIVES CONTAINING CHANNELIZER - Once a day sustained release solid oral dosage form of phenothiazine derivative preferably the dibenzothiazepine derivative and their pharmaceutically acceptable salts comprising of a channelizer, rate controlling polymer and suitable pharmaceutically acceptable excipients. The formulation of the present invention is in the form of tablet or capsule which provides a sustained drug action upto 24 hours upon single dose administration.07-15-2010
20120244216COATED PHARMACEUTICAL CAPSULE DOSAGE FORM - Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.09-27-2012
20120244215HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone C09-27-2012
20100178335Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability - The present invention relates to new formulations comprising acetylsalicylic acid or its derivatives an oil phase and a cyclodextria in soft capsules, characterized by a high stability.07-15-2010
20110059166HIGH STRENGTH SEAMLESS ALGINATE CAPSULES - The invention is directed to a seamless alginate capsule having a film encapsulating a fill material, in which the film comprises alginate, noncrystallizing plasticizer, and glycerol and in which a ratio by weight of noncrystallizing plasticizer to glycerol in the film is between about 1:1 and about 8:1. The invention is also directed to a method of making the seamless alginate capsules and to capsules made by the method. The capsules have excellent breaking strength and are resistant to oxidation of the fill material.03-10-2011
20100255083CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION AND PROCESS FOR ITS PREPARATION - The present invention relates to a controlled-release pharmaceutical formulation comprising at least one active ingredient dispersed in a matrix comprising at least one slow-release excipient comprising an association of at least one glycogen and at least one alginate with alkaline-earth metal salts, and a process for its preparation. The invention also relates to a slow-release excipient comprising an association of at least one glycogen and at least one alginate with alkaline-earth metal salts, and the process for its preparation, and its use for the preparation of slow-release pharmaceutical formulations.10-07-2010
20130216618SOFT CAPSULE BASED ON STARCH AND A METHOD AND DEVICE FOR THE PRODUCTION THEREOF - A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying the mixture by increasing the temperature of the mixture during and/or after the shaping process by more than 5° C.; and shaping the film to form a soft capsule. Soft capsules produced by this method have starch particles bonded to one another. A device for performing this method comprises a shaping device to enable shaping of the starch material to form a film, and a heating device to perform a heat treatment to destructure the starch during and/or after the shaping. It comprises a rotary die device.08-22-2013
20100239662MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. The second layer, which can be adjacent the first layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles in the first layer. The composition further comprises a superabsorbent material (for example, polycarbophil) disposed within the first layer, the second layer, or both the first layer and the second layer. When intact, the pharmaceutically active agent is released from the second layer faster than the pharmaceutically active agent in the first layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition. Also disclosed is a method of using the misuse preventative, controlled release composition to deliver at least one pharmaceutically active agent to a mammal, for example, a human, in need thereof.09-23-2010
20100239661PHARMACEUTICAL COMPOSITIONS OF URSODIOL - A pharmaceutical composition is disclosed. The composition comprises a therapeutically effective amount of active pharmaceutical ingredient that is Ursodiol or its pharmaceutically acceptable salts thereof with one or more pharmaceutically acceptable excipients, wherein said active pharmaceutical ingredient present in the form of micronized and unmicronized particles in the ratio about 5:95 to about 95:5.09-23-2010
20100255084Medicinal melting capsules for oral mucosal absorption - A medicinal melting capsule comprised of a material that has the same melting point as the human body temperature and includes a therapeutic amount of medication for use in treatment of a desired medical condition; wherein the medication has been modified for oral mucosal absorption; and a related method for delivering medication to an individual via oral mucosal absorption comprising the steps of providing a melting capsule comprised of a material, that has the same melting point as the human body temperature, and includes a therapeutic amount of medication for use in treatment of a desired medical condition; modifying said medication by manipulating the solvent, pH, buffer material and/or polarity to adjust for oral mucosal absorption; administering the capsule sublingually in the patient such that the capsule melts at the individual's body temperature and delivers the medication directly into the bloodstream of the individual quickly and without gastric complications.10-07-2010
20100209495GRANULATES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL PRODUCTS CONTAINING THEM - A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate.08-19-2010
20120141581CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism.06-07-2012
20120141582Thixotropic Oil Based Vehicle for Pharmaceutical Compositions - The present invention relates to a novel thixotropic oily vehicle comprising between about 0.2% to about 5% (w/w) of a colloidal silica and between about 0.2% to about 5% (w/w) of a hydrophilic polymer in an edible oil. The interaction between the hydrophylic polymer and the colloidal silica in the above concentration ranges confers thixotropy and a low viscosity under shear on the solution. The invention also relates to capsules filled with the above thixotropic solution used as a fill mass.06-07-2012
20130136792MULTI PHASE SOFT GEL CAPSULES, APPARATUS AND METHOD THEREOF - A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multiphase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.05-30-2013
20110008423PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULES OF PURIFIED MICROBIAL LIPASE AND METHODS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS - The present invention relates to pharmaceutical compositions comprising granules containing at least one recombinantly produced purified microbial lipase, the use of said pharmaceutical compositions for the manufacture of a medicament for the prevention or treatment of certain diseases or disorders like pancreatic endocrine insufficiency, and a process for the manufacture of said pharmaceutical compositions.01-13-2011
20110111019Novel Method for Producing Nanocapsules in the Absence of an Organic Solvent, and Nanocapsules Produced Thereby - The invention relates to a method for preparing an aqueous suspension of nanocapsules comprising an oily core surrounded by a polymeric shell, in which method the following phases are mixed: 05-12-2011
20100183709FORMULATION - The present invention relates to therapeutic formulations based on pumpkin products, in particular to encapsulated formulations for oral administration. A product of the invention comprises a hard gelatin capsule which encloses a unit dose of a formulation which comprises at least 50% by weight of one or more pumpkin product.07-22-2010
20100221324PH-DEPENDENT CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION FOR NON-OPIOIDS WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL - The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0. characterized in that the coating layer further contains 110 to 250% by weight, calculated on dry weight of the polymer mixture, of a non-porous inert lubricant and the is present in an amount of at least 60% by weight calculated on the weight of core.09-02-2010
20100112046FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME - The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.05-06-2010
20110244034SUSTAINED RELEASE DRUG DELIVERY SYSTEM - The invention discloses a controlled release dosage form comprising a therapeutically effective amount of a pharmaceutically active agent, illustrated by Acyclovir, that would release in about 12 hours not more than about 90% of the said active agent in a simulated gastric juice in a first order rate of release in a USP type 1 dissolution test, and not containing a solubilizer or a swelling enhancer or both, comprising (a) a tablet made from polymer matrix of at least two biocompatible polymers, illustrated by Carbopol 974P and polyethylene oxide, the said pharmaceutically active agent and pharmaceutically permitted excipients; the said tablet capable of rapid swelling without disintegration in the said simulated gastric juice to a size that shall result in its gastric retention in the stomach and start controlled release of the said active agent by starting controlled erosion as well as diffusion immediately after coming into contact with the said gastric juice, or (b) microspheres of ungrafted chitosan or a chitosan derivative illustrated by thiolated chitosan and trimethyl chitosan, or Carbopol incorporating the said active agent, wherein the said pharmaceutically active agent is not a polymeric molecule and after administration in stomach, the said microspheres adhare to the gastric mucosa for a long time releasing the active agent in a controlled way.10-06-2011
20100178334Oral Pharmaceutical Dosage Form Comprising as Active Ingredients a Proton Pump Inhibitor together with Acetyl Salicyclic Acid - The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present invention refers to a method for the manufacture thereof and the use thereof in medicine. The present invention also relates to a specific combination comprising esomeprazole, or an alkaline salt thereof or a hydrated form of any one of them, and acetyl salicylic acid for use as a medicament for the prevention of thromboembolic vascular events, such as myocardial infarction or stroke, and for the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid.07-15-2010
20090028935CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions.01-29-2009
20090214640DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MAKING SAME - The present invention relates to a delayed release pharmaceutical oral dosage form and method of making same. The delayed release dosage form comprises one or more active ingredients within a granulated composition, which further comprises one or more excipients selected from the group of solid aliphatic alcohols, fatty acid esters, mixtures of esters of saturated fatty alcohols and saturated fatty acids, natural waxes, synthetic waxes, hydrogenated castor oil, hydrogenated vegetable oil, gums, and mixtures thereof; and one or more polymers or copolymers exhibiting a pH-dependent solubility. The present invention also related to method of making these delayed release dosage form.08-27-2009
20110070300EXTENDED RELEASE DOSAGE FORMS OF METOPROLOL - The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.03-24-2011
20110070299DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF DULOXETINE - A pharmaceutical composition comprising duloxetine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient(s) characterised in that the duloxetine has a D03-24-2011
20090098200COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION - Compositions are provided comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochemical properties. The composition forms colloidal nanodispersion upon contact with aqueous media.04-16-2009
20110256217PULSATILE RELEASE COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL DRUG ABSORPTION - Delayed release oral pharmaceutical formulations and methods for enhanced intestinal drug absorption. The formulation comprises a first population of carrier particles comprising a drug and a penetration enhancer which are released at a first location in the intestine, and a second population of carrier particles comprising a penetration enhancer and a delayed release coating or matrix. This penetration enhancer is released at a second location in the intestine downstream from the first location and enhances absorption of the drug when it reaches the second location.10-20-2011
20080268038Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength - Provided are compositions and methods for increasing diet induced thermogenesis. Typically, the compositions are comprised of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine.10-30-2008
20080268037Autonomous method for oral delivery of a healing substance to a target place in gastrointestinal tract of humans or animals - A method for oral delivery of new drugs, big molecules, proteins, and healing substances to a target place in the body, via digestive tract, using mobile self-controlled capsules with sensors.10-30-2008
20120201876METHOD OF MANAGING HYPERCORTISOLEMIA, HEADACHE DISORDERS, NEUROPATHIC PAIN AND RELATED DISORDERS - The present disclosure relates to treatment and management of Cushing's syndrome, Headache disorders and Neuropathic using a composition comprising asiaticoside and madecasosside optionally along with at least one excipient. The treatment can be extended to Myalgia and other related disease conditions.08-09-2012
20120121700PHARMACEUTICAL FORMULATIONS COMPRISING VALGANCICLOVIR - Pharmaceutical formulations prepared by granulating valganciclovir or a salt thereof, using a nonaqueous solvent or hydro-alcohol.05-17-2012
20100285115Novel Antiretroviral Combination - The invention relates to pharmaceutical compositions containing a combination of atazanavir and ritonavir, to methods of making them, and their use in medicine.11-11-2010
20110020439DELAYED RELEASE COMPOSITIONS OF DULOXETINE - A delayed release dosage form comprising core comprising duloxetine or its pharmaceutically acceptable salts or derivatives thereof, optionally, other pharmaceutically acceptable excipient(s) thereof; intermediate layer; and enteric layer; wherein the dosage form comprises one/more dissolution enhancer(s), wherein the enteric layer comprises one/more enteric polymers other than hydroxypropylmethyl acetate succinate. A process of preparing a delayed release dosage comprising mixing pharmaceutically acceptable excipients with duloxetine or its pharmaceutically acceptable derivatives thereof; granulating the product of previous step compressing the granulate formed in previous step to form core, coating said core with intermediate layer followed by coating with one/more enteric polymers and optional finishing coating. A delayed release dosage form comprising: core comprising duloxetine or its pharmaceutically acceptable derivative thereof, intermediate layer and enteric layer comprising one/more enteric polymers other than hydroxypropylmethyl acetate succinate; wherein dosage form contains one/more dissolution enhancer(s) and has improved dissolution.01-27-2011
20110064801Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate03-17-2011
20100330170Flavored Vegetarian Cellulose Capsule and Methods for Producing said Capsule - A flavored vegetable starch capsule and the method of manufacture of the flavored capsule is provided. The capsule may comprise (a) from about 95% to about 100% parts by weight of cellulose, such as hydroxymethylcellulose; (b) from about 0.5% to about 5.5% by weight of a suitable hydrogenated saccharide, such as sorbitol; (c) from about 0.2 to about 2.5% of a lubricant, such as silicon dioxide; (d) up to about 10% purified water; to which is added about 1/10 parts by weight of liquid flavoring.12-30-2010
20110008424Sustained Release Solid Formulations and Methods of Manufacturing the Same - Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type excipient and copovidone, and thus, has increased compressibility and fluidity and reduced adhesiveness, and a method of preparing the same.01-13-2011
20110081413Pharmaceutical Compositions Comprising Phosphate-Binding Polymer - The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion source.04-07-2011
20100323005Sodium Ibuprofen Tablets and Methods of Manufacturing Pharmaceutical Compositions Including Sodium Ibuprofen - Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics. The formulations and processes are further advantageous because they can be produced in large quantities without an unacceptable number of defective tablets.12-23-2010
20110097396PEELING CAPSULE WITH INTEGRATED CARE EFFECT - A cosmetic capsule which can be topically applied and rubbed in and comprises a casing material and a filling material enclosed by the casing material. The casing material is composed of an emulsion which comprises one or more waxes that are solid above 25° C. and the filling material comprising a preparation which has an abrasive effect and comprises one or more abrasive peeling agents which are present in an oil or lipid mixture, a surfactant-containing preparation or an emulsion.04-28-2011
20100158997BLOW-MOLDED THIN-WALLED DRUG DELIVERY CAPSULES - A thin-walled capsule of defined permeability is produced by blow-molding an aqueous-based polymer composition.06-24-2010
20100158998FORMULATIONS COMPRISING VITAMIN D OR DERIVATIVES THEREOF - The present invention provides stable formulations of vitamin D or a derivative thereof, preferably cholecalciferol.06-24-2010
20100196465STABLE PHARMACEUTICAL COMPOSITION OF A WATER-SOLUBLE VINORELBINE SALT - A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water-soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet.08-05-2010
20100196466DRUG DELIVERY SYSTEM - A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided.08-05-2010
20120064153Compositions and Methods for Treating Centrally Mediated Nausea and Vomiting - Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.03-15-2012
20120308654ABUSE-PROOFED DOSAGE FORM - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.12-06-2012
20100021536ENHANCED-DIFFUSION CAPSULE - An ingestible capsule is provided for delivering medication to a subject. A capsule coating dissolves in a gastrointestinal tract of the subject. An inner core of the capsule has an outer surface associated therewith. The outer surface is disposed within the coating and expands when the coating dissolves. A medication is disposed on the outer surface, and the outer surface is configured such that the medication contacts an intestinal wall of the subject when the outer surface expands. Other embodiments are also provided.01-28-2010
20090191265Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients - A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.07-30-2009
20100221323Crystal Entecavir Formulation And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection, comprising the crystal entecavir as pharmaceutically active ingredients and pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have more stronger stabilization than that of amorphous entecavir under conditions of lighting, high temperature and high humidity.09-02-2010
20110111018COATED TABLET FORMULATIONS AND USES THEREOF - The present invention provides coated tablet formulations comprising neratinib maleate, and improved methods for making such coated tablets.05-12-2011
20080248102Rapidly Dissolving Pharmaceutical Compositions Comprising Pullulan - The present invention provides an orally dissolving capsule comprising pullulan, a plasticizer and a dissolution enhancing agent.10-09-2008
20100278909PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS - A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting point of the melt granulating agent to form a solid dispersion of the angiotensin II receptor antagonist in the melt granulating agent; and c) cooling the solid dispersion to form granules; wherein the melt granulating agent is the only granulating agent used to form the granules.11-04-2010
20110014282PHARMACEUTICAL COMPOSITION FOR POORLY SOLUBLE DRUGS - A pharmaceutical composition containing a solid dispersion of a poorly soluble active pharmaceutical ingredient, an amorphous carrier and a surfactant.01-20-2011
20110020438Crystallization Inhibitor and Its Use in Gelatin Capsules - The present invention describes soft gelatin capsules that encapsulate a water-insoluble active ingredient and an excipient composed of a crystallization inhibitor that stabilizes the water-insoluble inhibitor. The crystallization inhibitor being at least one mononacylglycerol compound whose acyl group is a fatty acid residue of 6-18 carbon atoms. The capsule contents are more resistant to turbidity, forming a coarse emulsion, and crystallization of the active ingredient compared with compositions absent the crystallization inhibitor.01-27-2011
20080311187CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substances (A) from the dosage form is at least partially delayed.12-18-2008
20120064154SOLID DRUG FOR ORAL USE - The present invention provides a solid oral dosage form pharmaceutical for the treatment of dysuria, which comprises, as an active ingredient, an indoline compound having an α03-15-2012
20090252787GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.10-08-2009
20120301541COMPRESSED CORE FOR PHARMACEUTICAL COMPOSITION - A compressed core for a pharmaceutical dosage form comprising a mixture of (a) at least one pharmaceutically acceptable organic acid, and (b) at least one pharmaceutically acceptable excipient is described. Such compressed core is useful for the preparation of pharmaceutical compositions containing a drug in which dissolution of the drug is favored in acidic environments. Also described are pharmaceutical compositions comprising such compressed core.11-29-2012
20090263477SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF - In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients.10-22-2009
20090017111TOLTERODINE BEAD - A controlled release tolterodine bead is formed having a microcrystalline cellulose core, a PVP-containing water soluble coating, a tolterodine drug layer, and a controlled release layer.01-15-2009
20110064800NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CYCLOSPORINE - The present invention is directed to a composition comprising a nanoparticulate cyclosporine having improved bioavailability. The nanoparticulate cyclosporine particles of the composition have an effective average particle size of less than about 2000 nm in diameter and are useful in the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases. The invention also relates to a controlled release composition comprising a cyclosporine or a nanoparticulate cyclosporine that in operation delivers the drug in a pulsed or bimodal manner for the prevention and treatment of organ transplant rejection and autoimmune diseases such as psoriasis, rheumatoid arthritis, and other related diseases.03-17-2011
20110064799Pancreatic Enzyme Compositions and Methods for Treating Pancreatitis and Pancreatic Insufficiency - Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.03-17-2011
20120003305Oral Dosage Forms Of Bendamustine - In the present invention there is provided an oral pharmaceutical composition, comprising bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient, which is a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide.01-05-2012
20120003306Pharmaceutical composition of nanoparticles for protein drug delivery - The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.01-05-2012
20120207825PHARMACEUTICAL COMPOSITIONS FOR REDUCING ALCOHOL-INDUCED DOSE DUMPING - A pharmaceutical composition is disclosed. The composition comprises a core comprising an active substance or a salt thereof; a separating layer comprising at least one sugar; and a functional layer comprising at least one pharmaceutically acceptable polymer, wherein the composition is resistant to dose dumping in presence of alcohol.08-16-2012
20120207824ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.08-16-2012
20120045506CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING NEUTRAL VINYL POLYMERS AND EXCIPIENTS - The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.1 to 30% by weight of a plasticizer whereby the excipients of the excipients portion b) are each calculated on the dry weight of the polymer portion a).02-23-2012
20100055173RELEASE OF STATINS IN THE INTESTINE - The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, a subcoat surrounding the core comprising at least one water soluble hydrophilic carrier and an outer coating. The core is optionally and preferably in the form of a tablet.03-04-2010
20100278908COMPOSITIONS INCORPORATING AGENTS FOR REDUCING CELLULITE AND UNAESTHETIC APPEARANCE ASSOCIATED THEREWITH AND FORMULATIONS CONTAINING THEM - The present invention relates to synergic compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith which comprise a base matrix constituted by conjugated linoleic acid (CLA), grape seed extract, beta-glucan, organic calcium and dry extract of pine bark together with complementary synergic agents of the matrix. The invention also relates to the use of such compositions and formulations containing said compositions.11-04-2010
20120156287Use of Vitelline Protein B as a Microencapsulating Additive - The present invention includes compositions and methods for the use of an encapsulation additive having between about 0.1 to about 30 percent isolated and purified vitelline protein B to provide for mixed and extended release formulations.06-21-2012
20120156286COMPOSITIONS AND METHODS FOR INCREASED DELIVERY OF COENZYME Q10 - Disclosed are compositions comprising Coenzyme Q10 and a cetylated fatty acid blend, pharmaceutical formulations comprising the same and methods of increasing the systemic concentration of Coenzyme Q10 in an individual, comprising administering the same to the individual.06-21-2012
20110091537Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile - The present invention relates to a solid oral pharmaceutical form, with modified release of at least one active ingredient, containing at least microparticles containing said active ingredient and at least one viscosifying agent in a form isolated from said microparticles of active ingredient, characterized in that said microparticles possess an average diameter ranging from 100 to 600 μm, and are formed by a core containing at least said active ingredient and coated with at least one coating layer, 04-21-2011
20110091538POLYMER ADAPTED TO RELEASE BIOACTIVE AGENTS IN VIVO, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARATION THEREOF - The present invention provides a Monodisperse Polymer Particles (MPP) adapted to release alkoxy groups by means of a hydrolyser, such that Monodisperse Bioactive Polymer Particles (MBPP) are obtained in vivo. The MBPP are characterized by (a) at least one naturally occurring or synthetic long molecular chain consisting of biologically stable backbones optionally crosslinked, further characterized by a molecular weight of at least 1 KD, comprising between 10 to 1,000,000 repeated covalently-linked small molecules with a functionality of at least one alkoxy releasing group per molecule; (b) a long dimension between 0.1 and 10 micrometers; and, (c) a zeta potential value of 30 to 130 mV at pH of about 7.0. The MBPP alter, inhibit, activate, induce or otherwise affect biological or chemical events in vivo.04-21-2011
20080292692Impermeable Capsules - A capsule comprising a core and a shell surrounding and enclosing the core, the shell comprising at least one first polymer having a first water solubility parameter, and at least one second polymer having a water solubility parameter higher than the first water solubility parameter, wherein the second polymer is crosslinked, and/or all of the at least one second polymer is present in an amount that is less than all of the at least one first polymer. Upon exposure to an aqueous medium, the first polymer begins to swell, and water begins to leak into the capsule. Also, the second polymer is attracted to the entering water. As the second polymer absorbs water and swells, the mean free space in the shell decreases and the tortuous pathway for materials crossing the boundary of the wall increases. As a result, leakage rates across the capsule wall decrease.11-27-2008
20100291199Compositions and Methods For The Treatment and Prevention of Disease - The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.11-18-2010
20110104268GALENIC APPLICATIONS OF SELF-EMULSIFYING MIXTURES OF LIPIDIC EXCIPIENTS - A subject-matter of the invention is novel pharmaceutical formulations which make it possible to improve the intestinal absorption of orally administered active principles, their process of preparation and the application of lipid excipients in combination with one or more surfactants and one or more cosurfactants for inhibiting efflux pumps.05-05-2011
20100092548CHEWABLE SOFTGEL CAPSULES - A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected to render flexible the outer shell composition, an anti-tacking agent in an amount selected to render the outer shell composition non-sticky, and water. In one embodiment the chewable soft capsule further comprises at least one starch in a range of 0.1% to 35% of the total weight of the shell composition. The chewable softgel capsule is suitable for encasing therein medicines, pharmaceutical compositions, nutraceuticals, vitamins, nutritional supplements, and the like.04-15-2010
20120121701PHARMACEUTICAL COMPOSITION OF PEPTIDE DRUG AND ENZYME-INHIBITION COMPOUNDS - The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.05-17-2012
20090130197EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT - An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.05-21-2009
20120128768ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY - The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.05-24-2012
20120128767THERAPEUTIC CALCIUM PHOSPHATE PARTICLES AND METHODS OF MAKING AND USING SAME - The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules.05-24-2012
20120164217SCENTED CAPSULES - The present invention relates to new scented hard capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration to humans or animals of products such as pharmaceuticals or cosmetics.06-28-2012
20120164216PHARMACEUTICAL COMPOSITION OF DULOXETINE OR PHARMACEUTICALLY - The invention relates to a taste masked pharmaceutical composition comprising duloxetine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. The invention further discloses an inclusion complex comprising duloxetine or pharmaceutically acceptable salts thereof with one or more cyclodextrin or derivatives thereof.06-28-2012
20110182985Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof - The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.07-28-2011
20120076855Oral testosterone composition - The composition for oral administration of testosterone to a man who has androgen deficiency and exhibits one or more symptoms of androgen deficiency, comprises testosterone and a mixture of soybean oil and ethanol.03-29-2012
20120177731CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF - The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.07-12-2012
20120177730Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.07-12-2012
20100272792STABILITY ADDITIVES FOR DRY DHA DOSAGE FORMS - The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration.10-28-2010
20090060993SOLID PHARMACEUTICAL COMPOSITION FOR ENHANCED DELIVERY OF COENZYME Q-10 AND UBIQUINONES - The present invention describes a solid oral dosage form of ubiquinones (e.g., ubidecarenone, coenzyme Q-10, idebenone or mixture thereof), providing on contact with water or body fluids the regulated release of an “in situ” formed oil-in-water emulsion with ubiquinone incorporated in the oil phase. Described formulation demonstrates improved bioavailability.03-05-2009
20120315327ANTI-DIABETIC COMPOSITION CONTAINING A PLANT EXTRACT OF ENGLERINA LECARDII - The invention relates to a pharmaceutical antidiabetic composition containing, among the active ingredients thereof, a plant extract of 12-13-2012
20120263786Pharmaceutical Formulations Containing an SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate10-18-2012
20120082719Compositions For Treating Chronic Viral Infections - The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections.04-05-2012
20120189692Pharmaceutical Compositions of Iron for Oral Administration - The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.07-26-2012
20120258167ORAL PHARMACEUTICAL COMPOSITION - The present application provides a method for treating or preventing Celiac disease. In one embodiment the method comprises administering to a patient in need thereof a composition comprising minicapsules, wherein the minicapsules comprise a steroid in a liquid, semi-solid or solid core, the minicapsules having release profiles to release the steroid in an active form at one or more sites along the gastrointestinal tract, the one or more sites comprising the proximal small intestine beginning at the duodenum and ending at the ileum. In a related embodiment the method comprises administering budesonide to a patient in need thereof in a pre-solubilised drug delivery format.10-11-2012
20110123609MULTIPLE UNIT DOSAGE FORM OF NIACIN - A multiple unit dosage form useful for treating or preventing hyperlipidemia and/or atherosclerosis, wherein multiple unit dosage form comprise of a therapeutically effective amount of niacin or its derivatives and one or more control releasing agent(s) and pharmaceutically acceptable excipients, weight percentages are based upon the total weight of the dosage form. The multiple unit dosage form may comprise of optionally other antihyperlipidemic agent, more preferably HMG CoA reductase inhibitor. The most preferable dosage form is capsule. Further a kit comprising one or more capsules co-packaged to provide multiple unit dosage form of niacin or its derivatives in combination with HMG CoA reductase inhibitor is disclosed.05-26-2011
20110123608PHARMACEUTICAL FORMULATION - The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.05-26-2011
20110123607DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF A WATER SOLUBLE, CATIONIC AND AMPHIPHILIC PHARMACEUTICALLY ACTIVE SUBSTANCE - A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises poorly water soluble nanoparticles formed by the API together with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer.05-26-2011
20110123606ORAL COMPOSITION CONTAINING AN ANTIPLATELET AGENT OF THE THIENOPYRIDINE FAMILY IN THE FORM OF FREE BASE - The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.05-26-2011
20100310650Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation - A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition.12-09-2010
20100330169Pharmaceutical Tablet Containing A Liquid Filled Capsule - In one aspect, the present invention features a tablet including a compressed core and a liquid filled capsule, wherein the compressed core includes a first pharmaceutically active agent, the compressed core has a cavity exposed on the surface of the core, and the capsule is contained within the cavity such that a portion of the capsule is visible on the surface of the tablet, wherein the capsule has a diameter of at least 500 microns.12-30-2010
20080299187Substances for Reducing Occurence of Major Cardiac Events in Humans - A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents.12-04-2008
20110045065SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF - The present invention relates to medicinal formulations having anti-oxidant, geroprotective and anti-ischemic activity. Said formulations include 3-hydroxy 2,4,6 trimethylpyridine, pharmaceutically acceptable salts, esters, derivatives and polymorphs thereof.02-24-2011
20110045064FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.02-24-2011
20110223245CONTROLLED-RELEASE FORMULATIONS OF PRAMIPEXOLE - A controlled-release pharmaceutical formulation, comprising pramipexole or a pharmaceutically acceptable salt of pramipexole, colloidal silicone dioxide, and glyceryl behenate.09-15-2011
20110229562PH-DEPENDENT CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION FOR NON-OPIOIDS WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL - The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.09-22-2011
20110236475GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.09-29-2011
20110250268Compositions and Methods for Inhibiting Gastric Acid Secretion - The present invention is related to novel oral compositions comprising an irreversible gastric H10-13-2011
20120282332COMPOSITION AND METHOD THEREOF - The present disclosure relates to a composition comprising Trigoneoside Ib and Vicenin-1 for treatment and management of Goodpasture's disease, Glomerulonephritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Idiopathic Thrombocytopenia Purpura. The present disclosure also relates to a method of obtaining the said composition from 11-08-2012
20120282333DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF MESALAMINE - The invention relates to a delayed release pharmaceutical composition of mesalamine comprising: a) granules comprising mesalamine or pharmaceutically acceptable salts thereof and a hydrophilic polymer; b) extragranular excipients; wherein the pharmaceutical composition is further coated with a single layer of polymer.11-08-2012
20110287092COMPOSITIONS COMPRISING DECITABINE AND TETRAHYDROURIDINE AND USES THEREOF - Compositions comprising decitabine and tetrahydrouridine for the treatment of blood disorders and hematological and solid malignancies are described.11-24-2011
20100215735Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the Compounds - Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing β-amyloid production, β-amyloid deposition, β-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease β-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.08-26-2010
20100203120PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS - An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 08-12-2010
20130017257DRY POWDER FORMULATION CONTAINING TIOTROPIUM FOR INHALATION - The present invention is related to a dry powder formulation containing tiotropium to be administered via inhalation, the use of said formulation in the treatment of respiratory diseases especially asthma and COPD (Chronic obstructive pulmonary disease), and the production process of said formulation.01-17-2013
20110159087Crosslinked Polymers - Disclosed herein are pharmaceutical compositions comprising wet granulated bile acid sequestrants having the general Formula I shown, and their process of preparation. The present invention also discloses process for preparation of Colesevelam hydrochloride, an antilipemic agent.06-30-2011
20110159086PHARMACEUTICAL FORMULATION COMPRISING A CB1-RECEPTOR COMPOUND IN A SOLID SOLUTION AND/OR SOLID DISPERSION - The present invention relates to a pharmaceutical formulation comprising 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as racemate or (S)-enantiomer or mixtures thereof in a solid solution and/or solid dispersion.06-30-2011
20110159085ABT-263 CAPSULE - A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.06-30-2011
20110159084RALOXIFENE PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations.06-30-2011
20110159083Nanoparticles for protein drug delivery - The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge. The bioactive agent is hydrophobic or lipophilic in nature and is associated with micelles before being encapsulated in nanoparticles.06-30-2011
20130171253COMPOSITIONS FOR THE VAGINAL AND ORAL ADMINISTRATION OF LACTOBACILLUS AND USES THEREOF - The present invention relates to compositions for the oral and vaginal administration of human Lactobacilli and uses thereof for physiologic restoration of the vaginal flora, physiologic maintenance of 07-04-2013
20110262532Controlled Release Hydrocodone Formulations - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C10-27-2011
20100055174CHEWABLE SOFTGEL CAPSULES - A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected to render flexible the outer shell composition, an anti-tacking agent in an amount selected to render the outer shell composition non-sticky, and water. In one embodiment the chewable soft capsule further comprises at least one starch in a range of 0.1% to 35% of the total weight of the shell composition. The chewable softgel capsule is suitable for encasing therein medicines, pharmaceutical compositions, nutraceuticals, vitamins, nutritional supplements, and the like.03-04-2010
20130115282POLYVALENT POLYMERIC MATRIX FOR MODIFIED RELEASE SOLID ORAL PREPARATIONS AND METHOD OF PREPARATION THEREOF - A polymeric matrix for oral administration with modified release and taste masking properties is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly and individually covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as the method of its preparation are also disclosed.05-09-2013
20130095177METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD - The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form containing fingolimod and accordingly intermediates, granules and oral dosage forms obtainable by that method.04-18-2013
20130115281PHARMACEUTICAL FORMULATIONS OF STATINS AND OMEGA-3 FATTY ACIDS FOR ENCAPSULATION - A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form comprising a statin compound and at least one liquid fill phase comprising Omega-3 fatty acids. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. The solid phase, liquid phase or coatings may further comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, or therapeutic substances, functional excipients or combinations thereof.05-09-2013
20130129820PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE - Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R05-23-2013
20130129819Pharmaceutical Formulations Containing An SGLT2 Inhibitor - Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate05-23-2013
20130142871ORAL DOSAGE FORM OF DEFERASIROX - The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 μm to 120 μm, and also to a method of producing it.06-06-2013
20110236474Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration - The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.09-29-2011
20120276196Pharmaceutical Compositions of a Neuroactive Steroid and Methods of Use Thereof - The present invention relates to pharmaceutical compositions of the neuroactive steroid 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, with properties desirable for use in treating mood disorders and the like. The pharmaceutical compositions provide sustained therapeutic plasma levels of 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one. The present invention also relates to methods of treating these disorders by administering the pharmaceutical compositions.11-01-2012
20120021051ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM - A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.01-26-2012
20120027852PHARMACEUTICAL COMPOSITION CONTAINING A "LIMUS" FAMILY IMMUNOSUPPRESSIVE MACROLIDE - A pharmaceutical formulation includes a Limus family immunosuppressive macrolide on a pharmaceutically acceptable excipient, which may be compounded as suitable for oral administration.02-02-2012
20120027851METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution.02-02-2012
20130195973EXTENDED RELEASE PHARMACEUTICAL DOSAGE FORMS OF CARBIDOPA AND LEVODOPA AND PROCESS OF PREPARATION THEREOF - The present invention relates to an extended-release pharmaceutical dosage form of carbidopa and levodopa comprising (i) an immediate-release unit of carbidopa and levodopa; (ii) an extended-release unit of carbidopa and levodopa; and (iii) an immediate or extended-release unit of a carboxylate salt. The present invention further provides a process of preparation thereof.08-01-2013
20130202690ENCAPSULATED PICOPLATIN - The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant.08-08-2013
20130202691MODIFIED STARCH DERIVATIVE-BASED MATRIX FOR COLON TARGETING - A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix.08-08-2013
20120301542EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF - The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.11-29-2012
20130209553EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF PRAMIPEXOLE - The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil, and one or more pharmaceutically acceptable excipients.08-15-2013

Patent applications in class With claimed designated perfecting feature in contents (e.g., excipient, lubricant, etc.)